Rilpivirine
Rilpivirine is a pharmaceutical drug with 22 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
7
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.2%
15 of 17 finished
11.8%
2 ended early
1
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Population Pharmacokinetics of Antiretroviral in Children
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed
Clinical Trials (22)
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Population Pharmacokinetics of Antiretroviral in Children
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed
A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
Effect on HIV Medications on EPC Cells
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
Darunavir and Rilpivirine Interactions With Levonorgestrel Implant
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Rilpivirine in Virologically Suppressed Adolescents
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
The Rilpivirine Cerebrospinal-fluid (CSF) Study
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 22